MVRIX Trademark

Trademark Overview

On Tuesday, July 5, 2022, a trademark application was filed for MVRIX with the United States Patent and Trademark Office. The USPTO has given the MVRIX trademark a serial number of 79347737. The federal status of this trademark filing is REGISTERED as of Tuesday, December 26, 2023. This trademark is owned by MVRIX Co., Ltd.. The MVRIX trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

Pharmaceutical product research; pharmaceutical development; pharmaceutical research; medicine research; medical research
mvrix

General Information

Serial Number79347737
Word MarkMVRIX
Filing DateTuesday, July 5, 2022
Status700 - REGISTERED
Status DateTuesday, December 26, 2023
Registration Number7251233
Registration DateTuesday, December 26, 2023
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 10, 2023

Trademark Statements

Goods and ServicesPharmaceutical product research; pharmaceutical development; pharmaceutical research; medicine research; medical research

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, August 19, 2022
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameMVRIX Co., Ltd.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressKR
Party NameMVRIX Co., Ltd.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressKR
Party NameMVRIX Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKR

Trademark Events

Event DateEvent Description
Thursday, April 20, 2023NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Thursday, August 18, 2022SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, August 19, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, August 23, 2022APPLICATION FILING RECEIPT MAILED
Wednesday, April 19, 2023ASSIGNED TO EXAMINER
Wednesday, April 19, 2023NON-FINAL ACTION WRITTEN
Wednesday, June 7, 2023REFUSAL PROCESSED BY MPU
Thursday, June 8, 2023NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Monday, June 26, 2023REFUSAL PROCESSED BY IB
Wednesday, August 30, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 30, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 30, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 1, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, September 20, 2023NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Wednesday, September 20, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, September 20, 2023NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Tuesday, October 10, 2023PUBLISHED FOR OPPOSITION
Tuesday, October 10, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 26, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, October 10, 2023NOTIFICATION PROCESSED BY IB
Tuesday, March 26, 2024FINAL DISPOSITION NOTICE SENT TO IB
Tuesday, December 26, 2023REGISTERED-PRINCIPAL REGISTER
Tuesday, March 26, 2024FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, July 12, 2024NEW REPRESENTATIVE AT IB RECEIVED
Monday, April 15, 2024FINAL DECISION TRANSACTION PROCESSED BY IB
Tuesday, March 26, 2024FINAL DISPOSITION PROCESSED

Related Keywords

mvrix research pharmaceutical medical medicine development product